Articles From: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Marvell International Limited to Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors


Acacia Research Corporation (NASDAQ: ACTG) announced today that its Progressive Semiconductor Solutions LLC subsidiary has entered into a settlement and patent license agreement with Marvell International Limited.
Sign-up for Acacia Subsidiary Enters into Settlement and Patent License Agreement with Marvell International Limited investment picks
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Innovative Display Technologies LLC subsidiary has entered into a settlement and patent license agreement with MiTAC Digital Corporation d/b/a Magellan and MiTAC International Corporation.
Sign-up for Acacia Subsidiary Enters into Settlement and Patent License Agreement with MiTAC Digital Corporation d/b/a Magellan and MiTAC International Corporation investment picks
Acacia Research Corporation (NASDAQ: ACTG) announced today that its Online News Link LLC subsidiary has entered into a settlement and patent license agreement with Wayfair LLC.
Sign-up for Acacia Subsidiary Enters into Settlement and Patent License Agreement with Wayfair LLC investment picks
2014/9/10
Praise for Shiva Rea: SILVER SPRING, Md., Sept.
Sign-up for Acacia TV is the Premier Destination to Stream Shiva Rea's Award-Winning Workouts investment picks
2014/8/19
ADVISORY, Aug.
Sign-up for Academy of Nutrition and Dietetics to Ring The NASDAQ Stock Market Closing Bell investment picks
Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced that it will release its second quarter 2014 earnings on Tuesday, July 29, 2014, after the market closes.
Sign-up for Acadia Healthcare Announces Date for Second Quarter 2014 Earnings Release investment picks
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the second quarter and six months ended June 30, 2014.
Sign-up for Acadia Healthcare Reports Second Quarter Adjusted EPS Increase of 23.1% to $0.32 on 20.5% Growth in Revenue investment picks
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company”) today announced that it has received the requisite consents in connection with its consent solicitation commenced on June 9, 2014 relating to an amendment (the “Amendment”) to the indenture (the “Indenture”) governing its 12.875% Senior Notes due 2018 (the “Notes”). Ipreo LLC, the information and tabulation agent for the consent solicitation, advised the Company that as of the expiration of the consent solicitations at 5:00 p.m., New York City time, on June 17, 2014, the Company had received consents that had not been withdrawn in respect of a majority in aggregate principal amount of the Notes outstanding as of the record date.
Sign-up for Acadia Healthcare Secures Requisite Consents to Amend its Indenture Related to its 12.875% Senior Notes due 2018 investment picks
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in the Robert W.
Sign-up for Acadia Healthcare to Present at Robert W. Baird & Co. 2014 Health Care Conference investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, announced the appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer, effective today.
Sign-up for ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous disorders, today announced that the U.S. Food and Drug Administration (FDA) has provisionally accepted the trade name “NUPLAZID”™ for pimavanserin.
Sign-up for ACADIA Pharmaceuticals Announces Trade Name NUPLAZID™ for Pimavanserin investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to NUPLAZID™ (pimavanserin) for the treatment of Parkinson’s disease psychosis.
Sign-up for ACADIA Pharmaceuticals Receives FDA Breakthrough Therapy Designation for NUPLAZID™ (Pimavanserin) for Parkinson’s Disease Psychosis investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the second quarter ended June 30, 2014.
Sign-up for ACADIA Pharmaceuticals Reports Second Quarter 2014 Financial Results investment picks
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2014 on Tuesday, August 5, 2014, after the U.S. financial markets close.
Sign-up for ACADIA Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 5, 2014 investment picks
Acadia Realty Trust (NYSE:AKR), today announced the Company’s dividend for the quarter ending September 30, 2014.
Sign-up for Acadia Realty Trust Announces Quarterly Dividend investment picks
Acadia Realty Trust (NYSE:AKR) today announced that it has completed both the previously-reported sale of six retail properties in Miami Beach, Florida owned by its fund platform and the acquisition of a retail property in Manhattan’s Soho submarket on behalf of its core portfolio.
Sign-up for Acadia Realty Trust Provides Update on $392 Million of Transactions investment picks
Acadia Realty Trust (NYSE:AKR) today reported operating results for the quarter ended June 30, 2014.
Sign-up for Acadia Realty Trust Reports Second Quarter 2014 Operating Results investment picks
Acadia Realty Trust (NYSE:AKR), will release its second quarter 2014 earnings on Tuesday, July 29, 2014 after market close.
Sign-up for Acadia Realty Trust to Announce Second Quarter 2014 Earnings on July 29, 2014 investment picks
Acadia Realty Trust (NYSE:AKR), will release its third quarter 2014 earnings on Tuesday, October 28, 2014 after market close.
Sign-up for Acadia Realty Trust to Announce Third Quarter 2014 Earnings on October 28, 2014 investment picks
Acadia Realty Trust (NYSE:AKR) today announced it is scheduled to participate at the Bank of America Merrill Lynch 2014 Global Real Estate Conference, which will be held on September 10 th and 11 th , 2014 in New York City.
Sign-up for Acadia Realty Trust to Participate at Bank of America Merrill Lynch Global Real Estate Conference investment picks
Acadia Realty Trust (NYSE:AKR) today announced it is scheduled to participate at the BMO Capital Markets 9 th Annual North American Real Estate Conference, which will be held on September 15 th and 16 th , 2014 in Chicago.
Sign-up for Acadia Realty Trust to Participate at BMO Capital Markets 9th Annual North American Real Estate Conference investment picks
2014/7/28
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0959650001&sourceType=1 http://www.ccnmatthews.com/logos/20091230-Acadian200.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Acadian Timber Corp. Reports Second Quarter Results investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0955541001&sourceType=1 http://www.ccnmatthews.com/logos/20091230-Acadian200.jpg VANCOUVER, BRITISH COLUMBIA --
Sign-up for Acadian Timber Corp.: Notice-2014 Second Quarter Results Conference Call and Webcast for Investors and Analysts investment picks
LAVAL, Quebec, July 15, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces its financial results for the first quarter ended May 31, 2014.
Sign-up for Acasti Announces First Quarter Results investment picks
2014/7/24
Phase II Open Label Trial results for prescription drug candidate, CaPre® to be presented on July 26, 2014 at 12:30 p.m. LAVAL, Quebec, July 24, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that it has been selected to give an oral presentation at the 19 th World Congress on Heart Disease.
Sign-up for Acasti Announces Oral Presentation on COLT Study Results at 19th World Congress on Heart Disease in Boston investment picks
LAVAL, Quebec, June 16, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the resignation of Xavier Harland as Chief Financial Officer of Acasti with immediate effect.
Sign-up for Acasti Announces Resignation of Chief Financial Officer investment picks
LAVAL, Quebec, July 9, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces the completion of two trials, the Phase II double-blind, placebo-controlled (TRIFECTA) study and the Pharmacokinetic (PK) trial.
Sign-up for Acasti Completes Phase II Double Blind (TRIFECTA) and Pharmacokinetic Trials investment picks
LAVAL, Quebec, June 20, 2014 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (" Acasti " or the " Corporation ") (Nasdaq:ACST) (TSX-V:APO), an emerging biopharmaceutical company focused on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment and prevention of certain cardiometabolic disorders, announces that at its Annual and Special Meeting (the "Meeting"), held on June 19, 2014, the Corporation's shareholders voted in favour of all items put forth at the Meeting and outlined in the Corporation's management proxy circular dated May 22, 2014 (the "Circular") available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml .
Sign-up for Acasti Reports Results of Annual and Special Meeting investment picks
WATERTOWN, Mass., July 14, 2014 (GLOBE NEWSWIRE) -- athenahealth, Inc. (Nasdaq:ATHN) , a leading provider of cloud-based services for electronic health record (EHR), practice management , and care coordination , today announced ACAView, a joint initiative between the Robert Wood Johnson Foundation (RWJF) and athenahealth to measure the impact of the Affordable Care Act (ACA) on providers, patients, and physicians from 2014 through 2016.
Sign-up for ACAView Report Shows Medicaid Gap Widening Under Affordable Care Act; No Growth in New Patient Volumes investment picks
Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced the appointment of Terrence C.
Sign-up for Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Acacia Subsidiary Enters into Settlement and Patent License Agreement with Marvell International Limited to Acceleron Pharma Appoints Terrence C. Kearney to its Board of Directors
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices